Here’s something we haven’t seen before: The U.S. Office of Research Integrity has issued a second notice for a former researcher at the National Institutes of Health, after determining she withheld information during the first investigation.
A former professor at the University of Washington, Brodie is currently involved in his third lawsuit challenging afinding of scientific misconduct and a seven-year funding ban handed down in 2010 by the U.S. Department of Health and Human Services’ Office of Research Integrity. He says that in the time since his case was heard by an administrative law judge at the ORI level, new evidence has come to light that shows he “did not have a ‘full and fair opportunity to litigate’ the issues.” His lawsuit sought a court order to have the ORI revisit its decision.
Last year, a U.S. District Court judge dismissed the case, saying it revisited old issues that had already been litigated, but Brodie appealed that decision. Now, his quest may have come to an end: On Nov. 27, the U.S. Court of Appeals for the D.C. Circuit dismissed the appeal. If he wants to continue the case, Brodie’s only remaining option is to appeal the decision to the U.S. Supreme Court.
According to an internal personnel announcement forwarded to us, on December 4, Partin will begin a 90-day stint at the Office of the Vice President for Research at the Uniformed Services University of the Health Sciences, which trains health professionals to support the U.S. military.
Partin declined to comment. A spokesperson for the Department of Health and Human Services (HHS), of which the Office of Research Integrity is a part, told us the agency cannot comment on personnel issues.
Linda Schutjer, a former colleague of Partin’s at Colorado State University, told us Partin was asked to leave:
When Retraction Watch began in 2010, our co-founders Ivan Oransky and Adam Marcus quickly realized they couldn’t keep up with the hundreds of retractions that appeared each year. And the problem has only gotten worse — although we’ve added staff, the number of retractions issued each year has increased dramatically. According to our growing database, just shy of 1,000 retractions were issued last year (and that doesn’t include expressions of concern and errata). So to get new notices in front of readers more quickly, we’ve started a new feature called “Caught our Notice,” where we highlight a recent notice that stood out from the others. If you have any information about what happened, feel free to contact us at firstname.lastname@example.org.
In 2011, the University of Florida assembled a misconduct report about one of its ob-gyn researchers, identifying falsified data in a 2010 paper. But when an investigator at the U.S. Office of Research Integrity reviewed the report, something didn’t feel right.
“I reviewed the data, and I thought [UF] didn’t do their due diligence,” said Kristen Grace, then an ORI investigator, now heading up the compliance department of the Office of Clinical Research at the University of Pennsylvania. “Because the extent of the the falsification was so great.”
The subject of the findings isn’t a stranger to our readers: We’ve already reported on nine retractions for Nasser Chegini, a former professor of obstetrics and gynecology at the University of Florida (UF) who had won more than $4 million in Federal grants. And Chegini, who retired in early 2012, had been under investigation since at least 2012, with the ORI asking UF to broaden that investigation at one point.
Indeed, the ORI’s notice states that eight of Chegini’s retractions resulted from the UF’s investigation. The ORI’s findings, however, stem from another paper, published in the Journal of Reproductive Immunology, which has not been retracted.
A 2014 paper containing data manipulated by a former graduate student has finally been retracted, two years after the U.S. Office of Research Integrity (ORI) published its findings.
In August 2015, the ORI published a report that Peter Littlefield, who was working on his PhD at the University of California, San Francisco (UCSF), had committed “research misconduct by falsifying and/or fabricating data” in two papers. Littlefield agreed to correct or retract the papers–one published in Chemistry & Biology and the other in Science Signaling.
When we contacted Chemistry & Biology back in August 2015, a spokesperson for Cell Press told us the journal was figuring out “the best way to correct the scientific record.”